Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo ® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small ...

High-yielding dividend stocks can be great investments to hold on to in your portfolio, but only if they're safe. Betting on ...

Halozyme Therapeutics (HALO) announced that Bristol Myers Squibb (BMY) received a positive opinion from the Committee for Medicinal Products ...

EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...

Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), ...

An award-winning pathologist who devoted his life to melanoma research became the first person to receive a novel ...

Investors seeking relief from stock market volatility should take a closer look at Bristol Myers Squibb (NYSE: BMY). At the ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was the target of a significant growth in short interest during the month ...

Bristol-Myers Squibb Company discovers ... in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma ...